Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Talquetamab-tgvs + Teclistamab + unspecified PD-1 antibody|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Talquetamab-tgvs||Talvey||JNJ64407564|JNJ 64407564|JNJ-64407564||CD3 Antibody 86||Talvey (talquetamab-tgvs) is a bispecific antibody that targets CD3 and GPRC5D, potentially resulting in increased immune response against GPRC5D-expressing tumor cells (PMID: 32040549). Talvey (talquetamab-tgvs) is FDA-approved for use in adult patients with relapsed or refractory multiple myeloma who have received four or more prior lines of therapy (FDA.gov).|
|Teclistamab||Tecvayli||JNJ-64007957|BCMAxCD3|JNJ 64007957|JNJ64007957||CD3 Antibody 86 TNFRSF17 Antibody 17||Tecvayli (teclistamab) is a bispecific antibody that targets CD3 and BCMA, potentially resulting in increased immune response against BCMA-expressing tumor cells (Blood Dec 2016, 128 (22) 5668). Tecvayli (teclistamab) is FDA approved for use in adult patients with relapsed or refractory multiple myeloma who have received four or more prior lines of therapy (FDA.gov).|
|unspecified PD-1 antibody||Experimental PD-1 antibody||Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 112|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05338775||Phase I||Talquetamab-tgvs + Teclistamab + unspecified PD-1 antibody||A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma||Recruiting||USA | FRA | ESP | DEU||0|